Join
Live feed
·
PRReleasevia Quantisnow
Zai Lab Limited logo

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

ByQuantisnow·Wall Street's wire, on your screen.
ZLAB· Zai Lab Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZLAB (Zai Lab Limited) and more on Quantisnow.